Polly Niravath, MD

  • Houston Methodist breast oncologist
  • Assistant Professor of Clinical Medicine in Oncology, Houston Methodist Institute for Academic Medicine
  • Assistant Professor of Clinical Medicine, Weill Cornell Medical College

Polly Niravath, MD

Areas of Expertise

  • Breast biopsy
  • Breast cancer
  • Cancer clinical trials
  • Chemotherapy
  • Pagets disease

Credentials

BOARD CERTIFICATION
Medical Oncology | University of Southern California, Los Angeles, California | 2011
Hematology | 2011
Internal Medicine | 2008
MEDICAL SCHOOL
University of California, Irvine, College of Medicine | 2005
RESIDENCY
Baylor College of Medicine - Houston, TX | 2008
FELLOWSHIP
Baylor College of Medicine - Houston, TX | 2011

Publications

Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
Anand, K, Patel, T, Niravath, P, Rodriguez, A, Darcourt, J, Belcheva, A, Boone, T, Ensor, J & Chang, J 2021, , Scientific Reports, vol. 11, no. 1, 82. https://doi.org/10.1038/s41598-020-80081-y

ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer
Koca, E, Niravath, PA, Ensor, J, Patel, TA, Li, X, Hemati, P, Wong, H, Qian, W, Boone, T, Zhao, J, Ramshesh, PV, Cohen, AL, Murthy, A, Nair, S, Darcourt, JG, Belcheva, A, Kaklamani, VG & Chang, JCN 2021, , Breast Cancer Research and Treatment, vol. 188, no. 2, pp. 433-439. https://doi.org/10.1007/s10549-021-06214-7

Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy
Burns, E, Koca, E, Xu, J, McLean, E, Lee, R, Patel, T, Chang, J & Niravath, P 2021, , Oncologist, vol. 26, no. 6, pp. e936-e942. https://doi.org/10.1002/onco.13722

The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
Lewis, GD, Haque, W, Farach, A, Hatch, SS, Brian Butler, E, Niravath, PA, Schwartz, MR, Bonefas, E & Teh, BS 2021, , Reports of Practical Oncology and Radiotherapy, vol. 26, no. 2, pp. 179-187. https://doi.org/10.5603/RPOR.a2021.0026



Comparison of outcomes between metaplastic and triple-negative breast cancer patients
Polamraju, P, Haque, W, Cao, K, Verma, V, Schwartz, M, Klimberg, VS, Hatch, S, Niravath, P, Butler, EB & Teh, BS 2020, , Breast, vol. 49, pp. 8-16. https://doi.org/10.1016/j.breast.2019.10.003


Omission of radiation therapy following breast conservation in older (=70 years) women with T1-2N0 triple-negative breast cancer
Haque, WM, Verma, V, Hsiao, KY, Hatch, S, Arentz, C, Szeja, S, Schwartz, M, Niravath, PA, Bonefas, E, Miltenburg, D, Butler, EB & Teh, BS 2019, , Breast Journal, vol. 25, no. 6, pp. 1126-1133. https://doi.org/10.1111/tbj.13443

Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia
Niravath, PA, Hilsenbeck, SG, Wang, T, Jiralerspong, S, Nangia, J, Pavlick, A, Ademuyiwa, F, Frith, A, Ma, C, Park, H, Rigden, C, Suresh, R, Ellis, M, Kent Osborne, C & Rimawi, MF 2019, , Breast Cancer Research and Treatment, vol. 177, no. 2, pp. 427-435. https://doi.org/10.1007/s10549-019-05319-4

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Patel, T, Ensor, Jr. JE, Creamer, SL, Boone, T, Rodriguez, AA, Niravath, PA, Darcourt, J, Meisel, JL, Li, X, Zhao, J, Kuhn, JG, Rosato, RR, Qian, W, Belcheva, A, Schwartz, MR, Kaklamani, VG & Chang, JC 2019, , Breast Cancer Research, vol. 21, no. 1, 100. https://doi.org/10.1186/s13058-019-1186-0


TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases
Freedman, RA, Gelman, RS, Anders, CK, Melisko, ME, Parsons, HA, Cropp, AM, Silvestri, K, Cotter, CM, Componeschi, KP, Marte, JM, Connolly, RM, Moy, B, Van Poznak, CH, Blackwell, KL, Puhalla, SL, Jankowitz, RC, Smith, KL, Ibrahim, N, Moynihan, TJ, OSullivan, CC, Nangia, J, Niravath, PA, Tung, N, Pohlmann, PR, Burns, R, Rimawi, MF, Krop, IE, Wolff, AC, Winer, EP & Lin, NU 2019, , Journal of Clinical Oncology, vol. 37, no. 13, pp. 1081-1089. https://doi.org/10.1200/JCO.18.01511

A Behavior-Modification, Clinical-Grade Mobile Application to Improve Breast Cancer Survivors' Accountability and Health Outcomes
Stubbins, R, He, T, Yu, X, Puppala, M, Ezeana, CF, Chen, S, Valdivia y Alvarado, M, Ensor, J, Rodriguez, A, Niravath, P, Chang, J, Wong, STC & Patel, T 2018, , JCO Clinical Cancer Informatics, no. 2, pp. 1-11. https://doi.org/10.1200/CCI.18.00054


Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer
Dalal, AA, Gauthier, G, Gagnon-Sanschagrin, P, Burne, R, Guérin, A, Niravath, P & Small, T 2018, , Advances in Therapy, vol. 35, no. 9, pp. 1356-1367. https://doi.org/10.1007/s12325-018-0764-3

Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer
Guérin, A, Goldschmidt, D, Small, T, Gagnon-Sanschagrin, P, Romdhani, H, Gauthier, G, Kelkar, S, Wu, EQ, Niravath, P & Dalal, AA 2018, , Advances in Therapy, vol. 35, no. 8, pp. 1251-1264. https://doi.org/10.1007/s12325-018-0740-y

Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer
Dalal, AA, Gagnon-Sanschagrin, P, Burne, R, Guérin, A, Gauthier, G, Small, T & Niravath, P 2018, , Advances in Therapy, vol. 35, no. 6, pp. 768-778. https://doi.org/10.1007/s12325-018-0701-5

Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2– Metastatic Breast Cancer:: A Network Meta-analysis
Ayyagari, R, Tang, D, Patterson-Lomba, O, Zhou, Z, Xie, J, Chandiwana, D, Dalal, AA & Niravath, PA 2018, , Clinical Therapeutics, vol. 40, no. 4, pp. 628-639.e3. https://doi.org/10.1016/j.clinthera.2018.03.004

Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
Goldschmidt, D, Dalal, AA, Romdhani, H, Kelkar, S, Guerin, A, Gauthier, G, Wu, EQ, Niravath, P & Small, T 2018, , Advances in Therapy, vol. 35, no. 4, pp. 482-493. https://doi.org/10.1007/s12325-018-0676-2

Languages

  • English
  • Spanish